Prospective study of first-choice topiramate therapy in newly diagnosed infantile spasms

Clinical Neuropharmacology

Volumn 29, Issue 6, 2006, Pages 343-349

  Zou, Li Ping ^a   Ding, Chang Huan ^a   Fang, Fang ^a   Sin, Ngai Chuen ^b   Mix, Eilhard ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Epilepsy; First choice; Infantile spasms; Topiramate

Indexed keywords

ANTIBIOTIC AGENT; CORTICOTROPIN; NITRAZEPAM; TOPIRAMATE; VALPROIC ACID;

ADD ON THERAPY; ANHIDROSIS; ANOREXIA; ANTIBIOTIC THERAPY; APPETITE DISORDER; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFANT; INFANTILE SPASM; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN STUDY; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT REDUCTION;

ANTICONVULSANTS; DRUG ADMINISTRATION SCHEDULE; ELECTROENCEPHALOGRAPHY; FOLLOW-UP STUDIES; FRUCTOSE; HUMANS; INFANT; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SPASMS, INFANTILE; TREATMENT OUTCOME;

EID: 33750918159     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.WNF.0000236768.54150.8C     Document Type: Article

References (29)

1. Appleton RE. West syndrome: long-term prognosis and social aspects. Brain Dev 2001;23:688-691.
2. Wong M, Trevathan E. Infantile spasms. Pediatr Neurol 2001;24:89-98.
3. Buoni S, Zannolli R, Strambi M, et al. Combined treatment with vigabatrin and topiramate in infantile spasms. J Child Neurol 2004;19:385-386.
4. Brunson KL, Eghbal-Ahmadi M, Baram TZ. How do the many etiologies of infantile spasms lead to excitability and seizures? The corticotropin releasing hormone excess hypothesis. Brain Dev 2001;23:533-538.
5. Appleton RE, Peters AC, Mumford JP, et al. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999;40:1627-1633.
6. Vanhatalo S, Paakkonen L, Nousiainen I. Visual field constriction in children treated with vigabatrin. Neurology 1999;52:1713-1714.
7. Glauser TA, Miles MV, Tang P, et al. Topiramate pharmacokinetics in infants. Epilepsia 1999;40:788-791.
8. Glauser TA, Clark PO, Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998;39:1324-1328.
9. Glauser TA, Clark PO, McGee K. Long-term response to topiramate in patients with infantile spasms. Epilepsia 2000;41:S91-S94.
10. Ormrod D, McClellan K. Topiramate: a review of its use in childhood epilepsy. Paediatr Drugs 2001;3:293-319.
11. Mikaeloff Y, de Saint-Martin A, Mancini J, et al. Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res 2003;53:225-232.
12. Li ST, Shen EY, Chiu NC, et al. Effect of topiramate on intractable seizures in Taiwanese children. Acta Neurol Taiwan 2004;13:59-63.
13. Zou LP, Zhang MH, Zhang SN, et al. Immunologic aspects of topiramate treatment in infantile spasms patients. Hong Kong J Paediatr 2003;8:31-34.
14. Hosain SA, Merchant S, Solomon GE, et al. Topiramate for the treatment of infantile spasms. J Child Neurol 2006;21:17-19.
15. White HS, Brown SD, Woodhead JH, et al. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997;28:167-179.
16. Watemberg N, Goldberg-Stern H, Ben-Zeev B, et al. Clinical experience with open-label topiramate use in infants younger than 2 years of age. J Child Neurol 2003;18:258-262.
17. Tomson T. Drug selection for the newly diagnosed patient: when is a new generation antiepileptic drug indicated? J Neurol 2004;251:1043-1049.
18. Dahlin MG, Ohman IK. Age and antiepileptic drugs influence topiramate plasma levels in children. Pediatr Neurol 2004;31:248-253.
19. Albsoul-Younes AM, Salem HA, Ajlouni SF, et al. Topiramate slow dose titration: improved efficacy and tolerability. Pediatr Neurol 2004;31:349-352.
20. Nelson LP, Savelli-Castillo I. New antiepileptic agents. Pediatr Dent 2004;26:58-62.
21. Levisohn PM. Safety and tolerability of topiramate in children. J Child Neurol 2000;15:S22-S26.
22. Mohamed K, Appleton R, Rosenbloom L. Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience. Seizure 2000;9:137-141.
23. Philippi H, Boor R, Reitter B. Topiramate and metabolic acidosis in infants and toddlers. Epilepsia 2002;43:744-747.
24. Takeoka M, Holmes GL, Thiele E, et al. Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia 2001;42:387-392.
25. Wasserstein AG, Rak I, Reife RA. Nephrolithiasis during treatment with topiramate. Epilepsia 1995;36(suppl 3):S153. [abstract].
26. Ritter F, Glauser TA, Elterman RD, et al. Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Epilepsia 2000;41(suppl 1):S82-S85.
27. Dreifuss F, Farwell J, Holmes G, et al. Infantile spasms. Comparative trial of nitrazepam and corticotropin. Arch Neurol 1986;43:1107-1110.
28. Rintahaka PJ, Nakagawa JA, Shewmon DA, et al. Incidence of death in patients with intractable epilepsy during nitrazepam treatment. Epilepsia 1999;40:492-628.
29. Tang Y, Glauser TA, Gilbert DL, et al. Valproic acid blood genomic expression patterns in children with epilepsy - a pilot study. Acta Neurol Scand 2004;109:159-168.